Tampa, Florida, United States – TheNewswire – April 13, 2022 – CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) has made progress on numerous patents that are pending. The latest correspondence from the European Patent Office(EPO) did not include any objections, indicating that the patent office intends to grant CTT Pharma’s European Patent in the near future, as stated by our Patent Counsel. Once granted this patent can be validated in 38 countries. Ryan Khouri, CEO of CTT Pharma, stated, “The indication for our European Patent is promising, as this patent would help CTT’s global footprint by allowing our potential clients the ability to reach customers in 38 countries.” CTT Pharma will continue to update our shareholders on this patent as more news becomes available.
CTT is a drug delivery technology company that successfully received Health Canada approval and helped to bring our first product to market as cannabinoid-infused “Dissolve Strips”. This successful launch sold out to only 85,000 medical patients online with no advertising in several weeks. Once dissolved, CTT Pharma’s strips enter the bloodstream bypassing the lungs and digestive tract including the liver. Our smoke-free dissolvable strips have better bioavailability, better absorption, faster onset, and can offer zero calories. Nicotine, CBD, THC, and many other actives can be used with our patented technology.
CTT common shares trade on the OTC market in the United States under the symbol “CTTH”
Contact Ryan Khouri at 813-606-0060